In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.

Oct 31 (Reuters) - Dexcom (DXCM.O), opens new tab shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...

Investing.com - Oppenheimer downgraded DexCom (NASDAQ:DXCM) stock rating from Outperform to Perform on Monday, citing multiple challenges facing the continuous glucose monitoring device maker.

Dexcom has recalled its G6, G7, ONE, and ONE+ continuous glucose monitor (CGM)receivers due to a speaker malfunction that could cause missed low or high blood sugar alerts. The recall, for which ...

DexCom Inc (NASDAQ:DXCM) reported accelerating revenue growth in its first quarter of 2025, though the continuous glucose monitoring (CGM) leader faces margin pressures as it expands its product ...